QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barrington-research-maintains-outperform-on-anika-therapeutics-maintains-15-price-target

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $15 p...

 barrington-research-maintains-outperform-on-anika-therapeutics-lowers-price-target-to-15

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the pric...

 anika-therapeutics-q2-adj-eps-013-beats-017-estimate-sales-2822m-beat-2770m-estimate

Anika Therapeutics (NASDAQ:ANIK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(...

 anika-therapeutics-topline-results-from-its-us-pivotal-trial-of-hyalofast-for-articular-knee-cartilage-defect-lesions-demonstrated-improvements-over-microfracture-but-missed-on-statistical-significance-of-the-pre-specified-co-primary-endpoints

Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specifie...

 barrington-research-maintains-outperform-on-anika-therapeutics-lowers-price-target-to-19

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the pric...

 barrington-research-maintains-outperform-on-anika-therapeutics-lowers-price-target-to-20

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the pric...

 us-stocks-likely-to-open-lower-after-a-brief-respite-add-exposure-to-equities-amid-pullback-says-expert

U.S. stock futures fell again on Thursday after a brief respite on Wednesday, following a softer-than-expected inflation print.

 barrington-research-maintains-outperform-on-anika-therapeutics-lowers-price-target-to-25

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the pric...

 anika-closes-divestiture-of-its-arthrosurface-business-and-intention-to-divest-of-parcus-medical-business

The sale of the Company's Arthrosurface business to Phoenix Brio, Incorporated closed today, October 31, 2024. The Company ...

 anika-therapeutics-q3-2024-adj-eps-025-misses-001-estimate-sales-3875m-miss-4208m-estimate

Anika Therapeutics (NASDAQ:ANIK) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION